The first curative interstitial photodynamic therapy for patients with localised recurrent prostate cancer
|SPECTRACURE AB (PUBL) - SpectraCure AB
|Funding from Vinnova
|SEK 500 000
|July 2017 - November 2017
Purpose and goal
The project´s goal was to develop a business plan for validation and commercialisation of SpectraCure´s method of treating patients with relapsed prostate cancer after radiotherapy. In addition, the business plan has been expanded to include primary treatment of prostate cancer patients. The latter patient group is a much larger market, but with a number of established treatment methods. The positive preliminary results from ongoing clinical study mean that we believe that our method should have a very good opportunity to establish itself as a standard treatment.
Expected results and effects
We have now updated the company´s business plan according to the Horizon 2020 phase 1 application. The following changes mean that we are now better equipped to meet the needs of the market and our patients: 1. Position our method as a primary treatment modality 2. Enable local / focal treatment of prostate cancer Overall, this will increase our potential market and offer our patients an flexible, and hopefully, more sophisticated method than the existing standard of care. This has been achieved through technical, clinical and economic development work.
Planned approach and implementation
A market analysis was commissioned by the NC Biotechnology Center, which indicates that the overall market for prostate cancer will increase 50-100% over a ten-year period. In discussions with our clinical partners, we have decided to target primary tumor treatment to meet the increasing patient need. In connection to this we can now offer focal treatment of prostate cancer. This reduces the risk of side effects in patients. Overall, it gives us a excellent opportunity to establish our treatment method in a very large market segment.